Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy


Friday, July 19, 2019

Saturday, July 20, 2019

Sunday, July 21, 2019

Monday, July 22, 2019

Friday, July 19, 2019

Welcome and Opening Keynote Addresses  
5-7 p.m.

Next generation CAR T cells
Crystal Mackall, Stanford University, Stanford, California

A path towards successful T cell therapy for solid cancers 
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Opening Reception
7-9 p.m.

Top of page

Saturday, July 20, 2019

7-8 a.m.                

Plenary Session 1: Cellular Therapy Clinical Updates (I)
8-10 a.m.

Chimeric antigen receptor T cell therapy for chronic lymphocytic leukemia
Saar Gill, University of Pennsylvania, Philadelphia, Pennsylvania

CAR-T antigen evasion: The emerging role for multi-targeted CAR therapy
David Miklos, Stanford University, Stanford, California

Advancing CAR T cells for the treatment of brain tumors
Christine Brown, City of Hope National Medical Center, Duarte, California 

10-10:30 a.m.

Plenary Session 2: CAR T Cell Engineering – Barriers for Targeting Solid Tumors
10:30 a.m.-12:30 p.m.

Engineering lymphocytes for the adoptive immunotherapy of solid tumors
Stephen Gottschalk, St. Jude Children’s Research Hospital, Memphis, Tennessee

Molecular and epigenetic programs defining tumor-specific T cell dysfunction and therapeutic reprogrammability
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York

Engineering T cells to eradicate tumors: It starts with the TCR but doesn't stop there
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, Washington

Lunch and Poster Session A
12:30-2:30 p.m.

Plenary Session 3: Scalability of T Cell Therapy – Driving Down Costs
2:30-4 p.m.

Allogene: Leading the next revolution in cell therapy
Barbra J. Sasu, Allogene Therapeutics, San Francisco, California

Scalability of T cell therapy
Gwendolyn Binder-Scholl, Adaptimmune, Philadelphia, Pennsylvania

Innovating and planning our way to improve affordability and accessibility for chimeric antigen receptor (CAR) T cell therapies
Heidi Zhang, Celgene Corp., Seattle, Washington

4-4:15 p.m.

Plenary Session 4: NK and Other Immune Cell Therapies
4:15-6:15 p.m.

Off-the-shelf CAR-engineered cord blood-derived NK cells for the treatment of cancer
Katy Rezvani, University of Texas MD Anderson Cancer Center, Houston, Texas

TGFβ-resistant T and NK cells for cancer
Catherine Bollard, Children’s National Health System, Washington, D.C.

Selective expansion of adaptive natural killer cells for cancer immunotherapy
Karl Johan Malmberg, The University of Oslo, Oslo, Norway

Top of page

Sunday, July 21, 2019

7:00-8:00 a.m.     
Plenary Session 5: Cellular Therapy Clinical Updates (II)
8-10 a.m.

CAR T-cell therapy for lymphomas: Current and future strategies
Sattva Neelapu, The University of Texas MD Anderson Cancer Center, Houston, Texas 

Expanding CAR T cell therapy to a wide spectrum of pediatric malignancies
Julie Park, Seattle Children's Hospital, Seattle, Washington

Addressing relapse associated with leukemic resistance to CAR T cells
Terry Fry, University of Colorado Denver and Children's Hospital Colorado, Aurora, Colorado

10-10:30 a.m.

Plenary Session 6: Optimization of Target Antigens for TCR and TIL
10:30 a.m.- 12:30 p.m.

Novel naturally presented targets for personalized T-cell therapies
Harpreet Singh, Immatics US, Inc., Houston, Texas

T cell receptor gene therapy for epithelial cancers
Christian Hinrichs, National Cancer Institute, Bethesda, Maryland

Personalized neoantigen-targeting adoptive TCR-T cell therapies for solid tumors
Alex Franzusoff, PACT Pharma, Inc., South San Francisco, California

Lunch on Own

12:30-2:30 p.m.

Plenary Session 7: Combination Therapy with Adoptive Cell Therapy

2:30-4:30 p.m.

Unveiling mechanisms of response and resistance to instruct next generation cancer immunotherapy
Aude Chapuis, Fred Hutchinson Cancer Research Center, Seattle, Washington

Role of marrow infiltrating lymphocytes in adoptive T cell therapy
Ivan Borrello, Johns Hopkins University, Baltimore, Maryland

Combining checkpoint blockade with CAR T cell therapy to augment response
Shannon Maude, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Reception and Poster Session B
4:30-6:30 p.m.

Top of page

Monday, July 22, 2019

7-8 a.m.

Plenary Session 8: Enhancing Immune Cell Function through Genetic Engineering
8-10 a.m.

Tumor infiltrating lymphocyte therapy for metastatic melanoma
Rodabe Amaria, MD Anderson Cancer Center, Houston, Texas

Enhancing CAR T cell therapy by enabling CAR T cell interaction with antigen-presenting cells
Clare Slaney, Peter MacCallum Cancer Center, Melbourne, Australia

Strategies to improve CAR T persistence and solid tumor targeting
Avery Posey, Jr., University of Pennsylvania, Philadelphia, Pennsylvania

10-10:30 a.m.

Plenary Session 9: Novel Approaches for Gene Delivery (Engineered Vectors and Viral Delivery Systems)
10:30 a.m.-12:30 p.m.

T cells genetically modified using non-viral gene transfer to target cancer
Laurence Cooper, Ziopharm Oncology, Boston, Massachusetts

Reprogramming human immune cell circuitry
Alexander Marson, University of California San Francisco, San Francisco, California 

Engineering smarter and stronger T cells for cancer immunotherapy
Yvonne Chen, University of California Los Angeles, Los Angeles, California

Closing Remarks
12:30 p.m.

Top of page